Abstract
Genomic technologies are now being used to identify new molecular markers or signatures for both diagnostic and prognostic purposes. Recently, we reported the molecular classification of pediatric osteosarcoma by expression profiling in an attempt to identify a signature that could predict the chemoresistance of a tumor before treatment is initiated. We identified a 45-gene signature that discriminates between good and poor responders to chemotherapy in osteosarcoma. Using this classifier, we can predict with 100% accuracy the chemoresponse of osteosarcoma patients prior to the initiation of treatment. These encouraging results suggest that the genomic approach will revolutionize the diagnosis and prognostication of osteosarcoma patients and improve their outcome through predictive, personalized care.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ochi K, Daigo Y, Katagiri T, et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004;24:647-655.
Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65:1748-1754.
Man TK, Chintagumpala M, Visvanathan J, et al. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res. 2005;65:8142-8150.
Link MP, Gebhardt MC, Meyers PA. In: Pizzo P, Poplack D, editors. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia: Lippincott-Williams & Wilkins; 2002. p. 1051-1089
Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76-84.
Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995;333:1380-1385.
Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep. 2002;9:171-175.
Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-2788.
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790.
Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12:423-431.
Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996;14:467-472.
Franzius C, Bielack S, Flege S, et al. Prognostic significance of (18) F-FDG and (99 m) Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002;43:1012-1017.
Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003;63:1759-1763.
Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33:49-54.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Lau, C.C. (2009). Molecular Classification of Osteosarcoma. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_26
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0284-9_26
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0283-2
Online ISBN: 978-1-4419-0284-9
eBook Packages: MedicineMedicine (R0)